This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

LifeSci Advisors Announces Investment Opinion On Adolor Corporation

LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Adolor Corporation (NasdaqGM: ADLR), a biopharmaceutical company focused on the development and commercialization of novel prescription central nervous system (CNS) and gastrointestinal (GI) products. Adolor is a leader in the development and commercialization of novel, opioid receptor-targeted therapeutics designed to maintain or improve opioid-like pain relief and reduce opioid side effects. Adolor’s currently marketed product, ENTEREG® (alvimopan), is a peripherally-acting mu opioid receptor antagonist approved for accelerating upper and lower GI recovery following bowel resection surgery.

“ADL5945, Adolor’s new therapy for the treatment of opioid-induced bowel dysfunction (OBD) with a focus on the primary symptom, opioid induced constipation (OIC), is a potent, orally available antagonist of peripheral mu opioid receptors in the GI tract that has the potential to provide substantial relief to this patient population and become a ‘best in class’ drug,” said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “To date, ADL5945 has been shown safe and has demonstrated strong therapeutic potential in early clinical trials. We are anticipating the imminent release of important Phase 2 data in 3Q 2011. ADL5945 appears to provide clinical benefit without disrupting the analgesic effects of patients’ pain medication. This therapy has the potential to reduce the suffering of millions of patients with chronic non-cancer pain and OIC where other therapies such as laxatives have failed. Pending encouraging Phase 2 results in approximately 200 patients, Adolor will be poised to begin the pivotal Phase 3 development program in early 2012. If approved, ADL5945 has the potential to become a blockbuster, with worldwide sales of more than $1 billion per year.”

In a 40-page Initiation Report by LifeSci Advisors, the clinical profiles of ADL5945 and other competing development candidates are elucidated. Adolor completed Phase 1 testing for ADL5945 in 2010 after testing the compound in two studies, a single ascending dose study in healthy volunteers designed to test safety and tolerability and establish the pharmacokinetic profile of the drug, and a multiple ascending dose (MAD) study that enrolled non-cancer pain patients on long-term opioid therapy with opioid induced constipation (OIC). The MAD study identified the maximum tolerated dose of 0.25 mg BID (Part A of the trial) and also evaluated safety, tolerability, and clinical effect of 0.1 mg BID (n = 8) and 0.25 mg BID (n = 8) vs. placebo (n = 4) over 2 weeks (Part B of the trial). ADL5945 was generally well tolerated with no reported serious adverse events (SAEs) and with most AEs GI-related and mild (none severe) in severity. The most commonly reported AE was nausea. The measure of efficacy was an increase over baseline in the weekly average number of spontaneous bowel movements (SBMs), which is the same primary outcome measure that is being used in the Phase 2 trials. Patients receiving 0.10 mg and 0.25 mg BID doses of ADL5945 experienced average increases during the trial period of 2.7 and 5.5 SBMs/week, respectively, compared with 1.5 SBMs/week for placebo. This study established the initial safety and proof of mechanism of action for ADL5945.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs